Karyopharm Therapeutics(US:KPTI) Prnewswire·2025-11-03 12:00Core Insights - Karyopharm Therapeutics reported a total revenue of $44.0 million for Q3 2025, an increase from $38.8 million in Q3 2024, with U.S. net product revenue from XPOVIO (selinexor) at $32.0 million, reflecting an 8.5% increase year-over-year [1][11][19] - The company reaffirmed its full-year 2025 total revenue guidance of $140 million to $155 million and U.S. XPOVIO net product revenue guidance of $110 million to $120 million [1][14] - The Phase 3 SENTRY trial for myelofibrosis has completed enrollment, with top-line data expected in March 2026 [2][8] Financial Performance - Total revenue for Q3 2025 was $44.0 million, compared to $38.8 million in Q3 2024 [11] - U.S. net product revenue was $32.0 million, up from $29.5 million in Q3 2024, driven by gross-to-net favorability [6][11] - License and other revenue increased to $12.0 million in Q3 2025 from $9.3 million in Q3 2024, primarily due to milestone-related revenue from Menarini [12] - R&D expenses decreased to $30.5 million in Q3 2025 from $36.1 million in Q3 2024, attributed to lower clinical trial costs [13] - SG&A expenses were $26.6 million in Q3 2025, down from $27.6 million in Q3 2024, reflecting cost reduction initiatives [16] Clinical Development - The Phase 3 SENTRY trial for myelofibrosis enrolled 353 patients and is evaluating selinexor in combination with ruxolitinib [6][22] - The company continues to enroll patients in the Phase 3 XPORT-EC-042 trial for endometrial cancer, with top-line data expected in mid-2026 [10][26] - Enrollment in the Phase 3 XPORT-MM-031 trial for multiple myeloma was completed in Q4 2024, with data expected in the first half of 2026 [7][13] Cash Position and Outlook - As of September 30, 2025, the company had cash, cash equivalents, and investments totaling $46.2 million, down from $109.1 million at the end of 2024 [20][43] - The company expects its existing liquidity will be sufficient to fund operations into Q2 2026 [14]